Q-omics provides the consensus-scored RXFP4 profile across patient tissues and cancer cell-line models. RXFP4 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, RXFP4 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, RXFP4 RNA expression shows 13,852 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight LIHC, KIRC, and KIRP as cancer lineages where RXFP4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RXFP4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RXFP4 survival associations across molecular data types. RXFP4 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RXFP4 RNA expression–survival associations across cancer types. High RXFP4 expression shows unfavorable associations in LIHC, ACC and ESCA, but favorable associations in SKCM, BLCA and LUAD. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for RXFP4 RNA expression.
This table summarizes RXFP4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RXFP4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RXFP4 shows lower tumor expression in KIRC, KICH, KIRP, LUAD and READ and higher tumor expression in STAD. The KIRC box plot shows higher RXFP4 RNA expression in normal versus tumor tissue (log2 FC = −0.596, t-test p < 0.001).
This table shows molecular features associated with RXFP4 in patient tissues and cancer cell lines. In patient samples, RXFP4 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, RXFP4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
